231 related articles for article (PubMed ID: 25323305)
1. Chronic hepatitis B therapy: available drugs and treatment guidelines.
Caviglia GP; Abate ML; Pellicano R; Smedile A
Minerva Gastroenterol Dietol; 2015 Jun; 61(2):61-70. PubMed ID: 25323305
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B virus infection - Dutch national guidelines.
Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL;
Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260
[TBL] [Abstract][Full Text] [Related]
3. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues.
Boni C; Laccabue D; Lampertico P; Giuberti T; Viganò M; Schivazappa S; Alfieri A; Pesci M; Gaeta GB; Brancaccio G; Colombo M; Missale G; Ferrari C
Gastroenterology; 2012 Oct; 143(4):963-73.e9. PubMed ID: 22796241
[TBL] [Abstract][Full Text] [Related]
4. Customizing the management of chronic hepatitis B virus infection.
Gish RG; Perrillo RP; Jacobson IM
Semin Liver Dis; 2007 Aug; 27 Suppl 1():9-17. PubMed ID: 17701845
[TBL] [Abstract][Full Text] [Related]
5. Why do I treat HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues?
Papatheodoridis GV
Liver Int; 2013 Feb; 33 Suppl 1():151-6. PubMed ID: 23286859
[TBL] [Abstract][Full Text] [Related]
6. Treatment of HBeAg-positive chronic hepatitis B with nucleos(t)ide analogues.
Leung N
Liver Int; 2011 Jan; 31 Suppl 1():85-9. PubMed ID: 21205143
[TBL] [Abstract][Full Text] [Related]
7. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
8. [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
Juszczyk J; Boroń-Kaczmarska A; Cianciara J; Flisiak R; Gładysz A; Halota W; Kryczka W; Malkowski P; Pawlowska M; Simon K;
Pol Merkur Lekarski; 2010 Aug; 29(170):103-6. PubMed ID: 20842822
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis B: Evolution over two decades.
Yuen MF; Lai CL
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
[TBL] [Abstract][Full Text] [Related]
10. Treatment of HBeAg-negative chronic hepatitis B patients with nucleos(t)ide analogues.
Papatheodoridis GV
Liver Int; 2011 Jan; 31 Suppl 1():95-103. PubMed ID: 21205145
[TBL] [Abstract][Full Text] [Related]
11. Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success.
Chien RN; Liaw YF
Best Pract Res Clin Gastroenterol; 2008; 22(6):1081-92. PubMed ID: 19187868
[TBL] [Abstract][Full Text] [Related]
12. HBeAg-negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues.
Lampertico P; Colombo M
Liver Int; 2009 Jan; 29 Suppl 1():130-2. PubMed ID: 19207976
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chronic hepatitis B].
Asselah T; Lada O; Boyer N; Martinot M; Marcellin P
Gastroenterol Clin Biol; 2008; 32(8-9):749-68. PubMed ID: 18775613
[TBL] [Abstract][Full Text] [Related]
14. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B.
Wong GL; Wong VW; Chan HL
J Viral Hepat; 2014 Dec; 21(12):825-34. PubMed ID: 25402543
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and prediction of HBsAg loss during therapy with analogues in patients affected by chronic hepatitis B HBeAg negative and genotype D.
Boglione L; D'Avolio A; Cariti G; Gregori G; Burdino E; Baietto L; Cusato J; Ghisetti V; De Rosa FG; Di Perri G
Liver Int; 2013 Apr; 33(4):580-5. PubMed ID: 23311449
[TBL] [Abstract][Full Text] [Related]
17. Antiviral effect of entecavir in nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy.
Chen CH; Hu TH; Hung CH; Wang JH; Lu SN; Lee CM
J Viral Hepat; 2014 Aug; 21(8):e55-64. PubMed ID: 24766327
[TBL] [Abstract][Full Text] [Related]
18. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
19. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.
Fung J; Lai CL; Seto WK; Yuen MF
J Antimicrob Chemother; 2011 Dec; 66(12):2715-25. PubMed ID: 21965435
[TBL] [Abstract][Full Text] [Related]
20. Current issues and future directions in treatment.
Hui CK; Lau GK
Semin Liver Dis; 2006 May; 26(2):192-7. PubMed ID: 16673297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]